How RWE Improves Evidence Generation Across the Product Life Cycle
Real-world evidence (RWE) is crucial for biopharmaceutical companies and other life sciences organizations to develop the right products for the marketplace. RWE is a powerful tool for regulators, too, in terms of continually assessing the safety, effectiveness, and value of new products or existing products in the context of new indications. In fact, there are […]
Linking Real-World Data is Like Making a Fine, Blended Wine
In the healthcare and life sciences industries, developments like the explosion of real-world data, new regulatory programs and frameworks, and a focus on AI and machine learning are fueling a transformation. Our podcast series, “Between Two Scientists,” explores why these changes are happening, and how the industry can respond, by interviewing experts in the field. […]
Highlights from Halifax: Six Themes from ICPE 2023
Last week in Halifax, the International Society for Pharmacoepidemiology (ISPE) held its annual conference, ICPE 2023. Attendees presented research findings and panelists discussed advancements in epidemiology methods, new regulatory developments, and the latest in health equity assessment and promotion. Here are just a few of the major themes that piqued our interest. The often complex […]
How Machine Learning is Improving Patient Outcomes: 5 Use Cases in 5 Minutes
Across the life sciences industry, machine learning is a powerful tool for analyzing patient data and improving the precision and efficiency of evidence generation. By addressing the limitations of real world data (RWD), machine learning can often enhance the capabilities of RWD to identify diseases earlier, trigger timely interventions, and recommend screenings and physician referrals. […]
Emerging Topics in Real-World Evidence: Part 2
Dr. Samy Suissa is a Co-Founder and Principal Investigator of the Canadian Network for Observational Drug Effect Studies (CNODES). He is Director of the Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research at the Jewish General Hospital and Professor, Departments of Epidemiology and Biostatistics and of Medicine, McGill University, in Montreal, Canada. Dr. Suissa […]
Emerging Topics in Real-World Evidence: Part 1
Dr. Peter Neumann is Director of the Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. His focus area is use of comparative effectiveness research and cost-effectiveness analysis in health […]
From Our Point of View: Highlights of DIA 2023
DIA 2023 was in Panalgo’s hometown of Boston last week and as usual, it did not disappoint. This year’s theme was ‘Illuminate’ – shining a light on many important topics such as diversity in clinical studies, artificial intelligence (AI), and personalized or precision medicine. Some newer concepts surfaced as well, including a provocative discussion of […]
Prepping for the Inflation Reduction Act: Why Manufacturers Need a Plan for Rapid RWE Generation
Since the passing of the Inflation Reduction Act (IRA) in August 2022, the healthcare industry has been bracing for the impact of several key provisions. Three of these policies—price negotiations, inflation-adjusted rebates, and the out-of-pocket spending cap—will be at least partially in place by the close of 2023. As manufacturers prepare for the effects of […]
How Life Sciences is Leveraging Machine Learning: 5 Use Cases in 5 Minutes
It’s no secret that machine learning is establishing itself as a powerful tool in the healthcare analytics industry. However, there is still some uncertainty around how to employ it. In our editions of Insights & Innovators: 5 Machine Learning Use Cases in 5 Minutes, we will take a look at five recent studies that used […]
Insights & Innovators: Is Lab Data the Secret Weapon for More Efficient Clinical Trials?
According to the National Institutes of Health (NIH), approximately 80% of research studies fail to meet their enrollment goals within the stated timeframes. Recruitment and trial design challenges can prolong the timeline for phase III studies, driving up costs and delaying market entry. While many sponsors use aggregated data and predictive analytics to improve the […]